HENDERSON, NV / ACCESSWIRE / September 28, 2018 / One stem cell play we like a lot is BioRestorative Therapies, Inc., (BRTX) a life sciences company focused on stem cell-based therapies. They recently reported the findings from Defined Health, which was engaged by BRTX to conduct an independent review of BRTX-100, the Company's lead cell therapy candidate designed to treat chronic Lumbar Disc Disease. Defined Health is a business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.
BRTX plans to use the results of the review to further refine its planned activities around BRTX-100, including potential licensing, co-development and commercialization activities.
Since announcing this news, BRTX has seen increased interest from investors this summer, which may lead to a major move in the near future.
Prior to the commencement of their trial may be the ideal time to take a look at BRTX.
The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from 2017 to 2025. All this comes from a report published by Transparency Market Research. From a global perspective, North America accounts for a leading share in the market due to rising instances of chronic diseases, increasing research investment and technological progress. The stem cells market in North America is projected to be worth USD 167.33 Billion by 2025.
The lead analyst of the report explains, ''The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market.
These here are a few stem cell plays you should pay attention to: BioRestorative Therapies, Inc. (BRTX), CRISPR Therapeutics AG (CRSP), Geron Corporation (GERN), Insys Therapeutics, Inc. (INSY), and Vericel Corporation (VCEL).
BioRestorative Therapies, Inc. (BRTX)
Market Cap: $18.31M Share Price: $2.27
BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, just announced that the Company has entered into a one-year material transfer agreement with the University of Pennsylvania providing the University access to the Company's proprietary brown adipose tissue fat cells.
CRISPR Therapeutics AG (CRSP)
Market Cap: $2.36B Share Price: $46.04
CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced the pricing of an underwritten public offering of 4,210,526 common shares at a public offering price of $47.50 per share, before underwriting discounts. In addition, underwriters have a 30-day option to purchase up to an additional 631,578 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $200 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about September 25, 2018, subject to customary closing conditions.
Geron Corporation, Inc. (GERN)
Market Cap: $1.13B Share Price: $6.16
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. On the company's recent earnings conference call, CEO Scarlett began by handing off to CFO Bloom. She reported on Geron's net loss for the quarter of $6.9 million in contrast to the comparable quarter in 2017 loss of $6.4 million. Geron's Q2, 2018 net reflects $3.2 million of research and development expenses for its share of costs under the collaboration agreement together with $4.2 million of general and administrative expenses.
Insys Therapeutics, Inc. (INSY)
Market Cap: $723.14M Share Price: $9.74
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently completed a human proof-of-concept study of dronabinol inhalation using a novel and patented breath-actuated device licensed exclusively from U.K.-based Senzer Ltd.
Vericel Corporation (VCEL)
Market Cap: $614.19M Share Price: $14.38
Vericel Corporation (VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences:
Nick Colangelo, president and CEO, will present at the Ladenburg 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 11:30 AM EDT
Nick Colangelo, president and CEO, will present at the Cantor Global Healthcare Conference in New York, NY on Wednesday, October 3, 2018 at 1:40 PM EDT
Dan Orlando, Chief Operating Officer, will present at the Cell & Gene Meeting on the Mesa in La Jolla, CA on, Thursday, October 4, 2018 at 5:15 PM PDT
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eightteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of BRTX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC.For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC